NASDAQ:AKTX Akari Therapeutics Q4 2025 Earnings Report $9.79 -0.91 (-8.50%) As of 12:33 PM Eastern ProfileEarnings HistoryForecast Akari Therapeutics EPS ResultsActual EPS-$2.68Consensus EPS -$0.03Beat/MissMissed by -$2.65One Year Ago EPSN/AAkari Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AAkari Therapeutics Announcement DetailsQuarterQ4 2025Date3/30/2026TimeAfter Market ClosesConference Call DateMonday, March 30, 2026Conference Call Time7:00AM ETConference Call ResourcesAnnual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsAnnual report(10-K) Akari Therapeutics Earnings HeadlinesAkari Therapeutics Participates in the Virtual Investor "Why Now" On-Demand ConferenceAugust 27, 2026 | globenewswire.comAkari Therapeutics (NASDAQ:AKTX) Raised to "Sell" at Wall Street ZenAugust 22, 2026 | americanbankingnews.comSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from collapsing — and billionaire Sam Altman is now an investor. This under-the-radar firm is drawing serious attention from those watching the energy infrastructure space closely.August 31 at 1:00 AM | Altimetry (Ad)Akari targets mid-2027 for human trial of differentiated cancer therapyAugust 18, 2026 | msn.comAkari Therapeutics Builds Momentum for AKTX-101 with Compelling Urothelial Cancer Data Supporting Differentiated ADC StrategyAugust 18, 2026 | globenewswire.comAkari Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Progress of AKTX-101 Towards Phase 1 and Strategic Collaboration for Its ADC Payload PlatformAugust 13, 2026 | globenewswire.comSee More Akari Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Akari Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Akari Therapeutics and other key companies, straight to your email. Email Address About Akari TherapeuticsAkari Therapeutics (NASDAQ:AKTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel complement inhibitors for the treatment of inflammatory and immunological diseases. The company’s research centers on modulation of the complement cascade, a key component of the innate immune system, with the goal of delivering targeted therapies to patients suffering from rare and severe disorders. Akari’s lead pipeline asset is sutimlimab, a humanized monoclonal antibody that selectively inhibits the C1s protein and is being evaluated in pivotal clinical studies for cold agglutinin disease. In addition, the company is advancing coversin, a small‐protein C5 inhibitor with potential applications in ophthalmology and hematology. These programs leverage Akari’s proprietary platform chemistry to achieve high specificity and subcutaneous dosing convenience. Headquartered in London, United Kingdom, with research and development operations in the United States, Akari Therapeutics was founded to translate cutting-edge complement science into first-in-class medicines. The company is led by an experienced management team with deep expertise in immunology, drug development and regulatory affairs, and it collaborates with academic institutions and patient organizations to support global clinical studies and future commercialization efforts. View Akari Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles The SaaSpocalypse Trade Is Cracking, and These 5 Stocks Are Leading HigherMarketBeat Week in Review – 08/24 - 08/28From SaaS-pocalypse to Perfect Storm: Workday’s AI Growth Story Strengthens3 Retail Stocks to Watch After a Big Consumer Earnings WeekRubrik’s AI Security Bet Could Power the Next Leg HigherPalo Alto’s Rally Has One Big Problem Ahead of EarningsDLocal Is Testing the Breakout Level That Could Change Its Stock Story Upcoming Earnings Medtronic (9/1/2026)Dell Technologies (9/1/2026)Palo Alto Networks (9/1/2026)Broadcom (9/2/2026)Hewlett Packard Enterprise (9/2/2026)Snowflake (9/2/2026)Ciena (9/3/2026)Oracle (9/8/2026)Adobe (9/10/2026)FedEx (9/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
